A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.
An Open-label, Randomized, Single Center, Crossover Study in Healthy Participants to Assess Lipoprotein Lipase Activity and Levels, and Triglyceride Levels After Heparin Exposure, in Both Fasted and Postprandial State
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
-
Groningen, Netherlands, 9728 NZ
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy subject
- Male or female
- 18 to 65 years, inclusive, at the time of signing informed consent
- Body mass index:18.0 kg/m ^2 to 29.9 kg/m^2, inclusive, at the time of signing informed consent
- Body weight greater than or equal to 50 kg at the time of signing informed consent
Exclusion criteria:
- Using tobacco products within 60 days prior to the first drug administration.
- Any kind of coagulation disorder or any first degree family members with major bleeding tendency.
- History of anemia, thrombocytopenia, HIT, other blood disorders, or any clinically relevant bleeding (epistaxis).
- Exposure to heparin (unfractionated heparin or low molecular weight heparin) within 100 days prior to the first dose of heparin.
- Participation in any clinical study of an approved or non-approved investigational medicinal product within 30 days (or 5 half-lives of the investigational medicinal product, whichever is greater) before screening. If the half-life of the investigational medicinal product is unknown, subjects participating in a clinical trial in the 6 months prior to (the first) treatment administration will be excluded.
- Any kind of coagulation disorder or any first degree family members with major bleeding tendency.
- Unwillingness to consume the entire high-fat standardized meal (e.g. vegetarians, vegans and subjects who follow special diets).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group 1 (low dose-high dose)
Participants receive 25 IU/kg heparin on days 1 and 2, and 50 IU/kg Heparin on days 4 and 5
|
intravenous [iv] injection
|
|
Experimental: Group 2 (high dose-low dose)
Participants receive 50 IU/kg heparin on days 1 and 2, and 25 IU/kg Heparin on days 4 and 5
|
intravenous [iv] injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in Lipoprotein Lipase (LPL) levels before and after heparin exposure both in fasted and postprandial state
Time Frame: day -1 to day 6
|
ng/ml
|
day -1 to day 6
|
|
Change from baseline in LPL activity before and after heparin exposure both in fasted and postprandial state
Time Frame: day -1 to day 6
|
µmol/l/min
|
day -1 to day 6
|
|
Change from baseline in Triglycerides (TG) levels before and after heparin exposure both in fasted and postprandial state
Time Frame: day -1 to day 6
|
mmol/L
|
day -1 to day 6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in apolipoprotein CII (APOCII) levels before and after heparin exposure both in fasted and postprandial state
Time Frame: day -1 to day 6
|
mg/L
|
day -1 to day 6
|
|
Change from baseline in APOCIII levels before and after heparin exposure both in fasted and postprandial state
Time Frame: day -1 to day 6
|
mg/dl
|
day -1 to day 6
|
|
Change from baseline in total cholesterol levels before and after heparin exposure both in fasted and postprandial state
Time Frame: day -1 to day 6
|
mmol/L
|
day -1 to day 6
|
|
Change from baseline in Free fatty acids (FFA) levels before and after heparin exposure both in fasted and postprandial state
Time Frame: day -1 to day 6
|
mmol/L
|
day -1 to day 6
|
|
Change from baseline in Lipoprotein profiling (very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), high-density lipoprotein (HDL) before and after heparin exposure both in fasted and postprandial state
Time Frame: day -1 to day 6
|
mmol.L-1
|
day -1 to day 6
|
|
Change from baseline in adverse events (AEs) before and after heparin exposure both in fasted and postprandial state
Time Frame: day -1 to day 6
|
Number of events
|
day -1 to day 6
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NN6633-4955
- 2021-005899-18 (EudraCT Number)
- U1111-1270-0957 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.